Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rupestonic acid is a naturally occurring sesquiterpene, primarily isolated from the medicinal plant *Artemisia rupestris*. It has demonstrated a range of pharmacological activities, including anti-inflammatory, hepatoprotective, and antiviral (particularly anti-influenza) effects. Recent research highlights its potential as an antineoplastic agent, specifically in hepatocellular carcinoma (HCC). Its mechanism involves direct binding to and destabilization of enolase 1 (ENO1), which subsequently suppresses the PI3K/Akt/FOXO signaling pathway. This molecular interaction leads to G0/G1 cell cycle arrest and triggers apoptosis through the mitochondrial pathway. Additionally, rupestonic acid has been shown to enhance the cytotoxic efficacy of paclitaxel in HCC cell lines, suggesting potential for combination therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rupestonic acid.